Follow-up after COPD exacerbation
Official title: A Multicenter Study of the Impact of a COPD Identification and Referral System on Patient Follow Up and Outcomes After an Acute COPD Exacerbation Resulting in an Emergency Department Visit or Hospitalization
Run by Viz.ai, Inc. · NCT07118306 · Data updated 2026-11-12
This project will try an AI-enabled workflow tool (Viz COPD) to see if it increases respiratory specialist follow-up and improves outcomes after a COPD flare-up in patients seen in the emergency department.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 40 Years and up |
| Sex | All |
| Enrollment | 485 (estimated) |
| Sponsor | Viz.ai, Inc. Industry-sponsored |
| Locations | 5 sites (Park Ridge, Illinois and 4 other locations) |
| Status | Recruiting |
| Started | February 27, 2026 |
| Main results expected | July 2027 |
| Study ends | December 2027 |
| Registry record updated | September 2, 2026 |
| Trial ID | NCT07118306 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 40 or older with a clinical diagnosis of COPD who present to the emergency department with a moderate or severe exacerbation and who are on dual or triple long-acting bronchodilator inhaler therapy.
✕Probably not a fit
Patients unlikely to benefit include those on bronchodilator monotherapy, with tracheostomy, advanced cancer, prior lung transplant, discharged to hospice, those who left against medical advice, or who died during hospitalization.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study compares patients exposed to an AI-enabled clinical workflow tool (Viz COPD) with a historical control cohort to measure respiratory specialist follow-up and downstream clinical outcomes after an acute COPD exacerbation. The Experimental cohort is collected prospectively with the tool active, the Control cohort is retrospective, and an Exploratory cohort includes both retrospective and prospective data. Primary outcomes include rates and timing of specialist follow-up, rehospitalizations, emergency visits, and mortality within a defined follow-up window. Data are gathered from electronic health records and workflow logs without changing standard clinical treatments.
Why it matters
Potential benefit: If successful, this could increase timely specialist follow-up after COPD exacerbations and reduce readmissions and other adverse outcomes.
How similar studies have gone: Related AI-enabled workflow tools have improved timeliness of specialist notification in acute conditions like stroke, but applying this approach specifically to COPD exacerbation follow-up is relatively novel with limited published evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 40 years or older at the time of arrival to the emergency department. * Patients with a clinical diagnosis of COPD who present to the emergency department for a moderate or severe COPD exacerbation. * A moderate exacerbation is defined as an acute exacerbation requiring either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics. * A severe exacerbation is defined as an acute exacerbation requiring hospitalization, or observation for \>24 hours in emergency department/urgent care facility or resulting in death. * Patients on dual (LABA/LAMA, LABA/ICS, LAMA/ICS) or triple (LABA/LAMA/ICS) long-acting bronchodilator inhalers. Exclusion Criteria: * Patients on bronchodilator inhaler monotherapy. * Patients leaving against medical advice or expiring during hospitalization. * Patients with tracheostomy. * Patients with advanced cancer. * Patients who have received a lung transplant. * Discharge to hospice care. * Transfer to another hospital.
Where it's running
-
Advocate Lutheran General Hospital
Park Ridge, Illinois, United States Recruiting -
Cooper University Health Care
Cherry Hill, New Jersey, United States Recruiting -
Thomas Jefferson University
Philadelphia, Pennsylvania, United States Recruiting -
Inova Fairfax Hospital
Falls Church, Virginia, United States Not yet recruiting -
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, United States Not yet recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Enhanced COPD care for people being checked for lung cancer
This project will test whether finding and treating COPD early in people being checked for possible lung cancer helps symptoms, lung function, and overall care.
-
High-Flow Nasal Cannula vs Noninvasive Ventilation in COPD with Hypercapnia
This study tests whether a high-flow nasal cannula can better support gas exchange and comfort compared with noninvasive ventilation in COPD patients with mild-to-moderate elevated CO2.
-
Risk-based lung cancer screening in COPD patients using ML and clinical models
This study tests whether a PLCOm2012 risk model plus a machine learning model can spot COPD patients at high risk for lung cancer to see if they benefit from low-dose CT screening.
-
Biologics for Type 2 Inflammation in Asthma and COPD in Real World
This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.
-
Nebulized vs handheld maintenance therapy for COPD patients with limited benefit from inhalers
This trial tests whether switching to a breath-enhanced nebulizer with similar COPD meds helps people who don’t get enough relief from their current handheld inhalers.
-
New breathing tests to diagnose airway disease in hospital and community settings
This study tests whether newer breathing tests can correctly diagnose COPD and airway disease as well as standard spirometry, using tests like capnography and oscillometry in hospital and community settings.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.